Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

MGTS reported for 2022 according to IFRS

3/3/23 MGTS

RusHydro's IFRS profit in 2022 halved

3/3/23 HYDR

The number of open accounts at Mosbirzha has exceeded 24 million

3/3/23 MOEX

MTS net profit in 2022 decreased by almost 50%

3/3/23 MTSS

PhosAgro's net profit in 2022 increased by more than 40%

3/3/23 PHOR

Ford creates new division in AI technology

3/3/23 F

Board of Directors of Phosagro recommended that dividends be paid for 2022

3/3/23 PHOR

Tesla ramped up production of electric cars in China in February

3/3/23 TSLA

Tinkoff Bank suspended currency transfers to Georgia

3/3/23 T

The volume of transactions in foreign stocks on SPCEX in February remained almost unchanged from January

3/3/23 SPBE